Literature DB >> 33628349

A Follow-Up Study of Lung Function and Chest Computed Tomography at 6 Months after Discharge in Patients with Coronavirus Disease 2019.

Qian Wu1,2, Lingshan Zhong2,3, Hongwei Li1,2, Jing Guo1,2, Yajie Li1,2, Xinwei Hou1,2, Fangfei Yang1,2, Yi Xie2,4, Li Li1,2, Zhiheng Xing2,3.   

Abstract

We aimed to investigate changes in pulmonary function and computed tomography (CT) findings in patients with coronavirus disease 2019 (COVID-19) during the recovery period. COVID-19 patients underwent symptom assessment, pulmonary function tests, and high-resolution chest CT 6 months after discharge from the hospital. Of the 54 patients enrolled, 31 and 23 were in the moderate and severe group, respectively. The main symptoms 6 months after discharge were fatigue and exertional dyspnea, experienced by 24.1% and 18.5% of patients, respectively, followed by smell and taste dysfunction (9.3%) and cough (5.6%). One patient dropped out of the pulmonary function tests. Of the remaining 54 patients, 41.5% had pulmonary dysfunction. Specifically, 7.5% presented with restrictive ventilatory dysfunction (forced vital capacity <80% of the predicted value), 18.9% presented with small airway dysfunction, and 32.1% presented with pulmonary diffusion impairment (diffusing capacity for carbon monoxide <80% of the predicted value). Of the 54 patients enrolled, six patients dropped out of the chest CT tests. Eleven of the remaining 48 patients presented with abnormal lung CT findings 6 months after discharge. Patients with residual lung lesions were more common in the severe group (52.6%) than in the moderate group (3.4%); a higher proportion of patients had involvement of both lungs (42.1% vs. 3.4%) in the severe group. The residual lung lesions were mainly ground-glass opacities (20.8%) and linear opacities (14.6%). Semiquantitative visual scoring of the CT findings revealed significantly higher scores in the left, right, and both lungs in the severe group than in the moderate group. COVID-19 patients 6 months after discharge mostly presented with fatigue and exertional dyspnea, and their pulmonary dysfunction was mostly characterized by pulmonary diffusion impairment. As revealed by chest CT, the severe group had a higher prevalence of residual lesions than the moderate group, and the residual lesions mostly manifested as ground-glass opacities and linear opacities.
Copyright © 2021 Qian Wu et al.

Entities:  

Year:  2021        PMID: 33628349      PMCID: PMC7881736          DOI: 10.1155/2021/6692409

Source DB:  PubMed          Journal:  Can Respir J        ISSN: 1198-2241            Impact factor:   2.409


  16 in total

1.  Chronic lung lesions in COVID-19 survivors: predictive clinical model.

Authors:  Carlos Roberto Ribeiro Carvalho; Rodrigo Caruso Chate; Marcio Valente Yamada Sawamura; Michelle Louvaes Garcia; Celina Almeida Lamas; Diego Armando Cardona Cardenas; Daniel Mario Lima; Paula Gobi Scudeller; João Marcos Salge; Cesar Higa Nomura; Marco Antonio Gutierrez
Journal:  BMJ Open       Date:  2022-06-13       Impact factor: 3.006

Review 2.  Pulmonary function test and computed tomography features during follow-up after SARS, MERS and COVID-19: a systematic review and meta-analysis.

Authors:  Christopher C Huntley; Ketan Patel; Shahnoor-E-Salam Bil Bushra; Farah Mobeen; Michael N Armitage; Anita Pye; Chloe B Knight; Alyaa Mostafa; Marie Kershaw; Aishah Z Mughal; Emily McKemey; Alice M Turner; P Sherwood Burge; Gareth I Walters
Journal:  ERJ Open Res       Date:  2022-05-30

3.  High-dose steroids for the treatment of severe COVID-19: a new therapeutic tool?

Authors:  Paolo Cameli; Laura Bergantini; Miriana d'Alessandro; Elena Bargagli
Journal:  Intern Emerg Med       Date:  2021-04-19       Impact factor: 3.397

Review 4.  Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis.

Authors:  Mohamad Salim Alkodaymi; Osama Ali Omrani; Nader A Fawzy; Bader Abou Shaar; Raghed Almamlouk; Muhammad Riaz; Mustafa Obeidat; Yasin Obeidat; Dana Gerberi; Rand M Taha; Zakaria Kashour; Tarek Kashour; Elie F Berbari; Khaled Alkattan; Imad M Tleyjeh
Journal:  Clin Microbiol Infect       Date:  2022-02-03       Impact factor: 13.310

5.  Long-term changes in pulmonary function among patients surviving to COVID-19 pneumonia.

Authors:  Alessia Fumagalli; Clementina Misuraca; Achille Bianchi; Noemi Borsa; Simone Limonta; Sveva Maggiolini; Daniela Rita Bonardi; Andrea Corsonello; Mirko Di Rosa; Luca Soraci; Fabrizia Lattanzio; Daniele Colombo
Journal:  Infection       Date:  2021-10-15       Impact factor: 7.455

6.  Plasma proteomic and metabolomic characterization of COVID-19 survivors 6 months after discharge.

Authors:  Hongwei Li; Xue Li; Qian Wu; Xing Wang; Zhonghua Qin; Yaguo Wang; Yanbin He; Qi Wu; Li Li; Huaiyong Chen
Journal:  Cell Death Dis       Date:  2022-03-14       Impact factor: 9.685

Review 7.  The Short- and Long-Term Clinical, Radiological and Functional Consequences of COVID-19.

Authors:  Yang Gao; Wei-Quan Liang; Yi-Ran Li; Jian-Xing He; Wei-Jie Guan
Journal:  Arch Bronconeumol       Date:  2022-04-13       Impact factor: 6.333

8.  A systematic review on physical function, activities of daily living and health-related quality of life in COVID-19 survivors.

Authors:  Katna de Oliveira Almeida; Iura Gonzalez Nogueira Alves; Rodrigo Santos de Queiroz; Marcela Rodrigues de Castro; Vinicius Afonso Gomes; Fabiane Costa Santos Fontoura; Carlos Brites; Mansueto Gomes Neto
Journal:  Chronic Illn       Date:  2022-04-11

Review 9.  Effects of SARS-CoV-2 Inflammation on Selected Organ Systems of the Human Body.

Authors:  Marta Kopańska; Edyta Barnaś; Joanna Błajda; Barbara Kuduk; Anna Łagowska; Agnieszka Banaś-Ząbczyk
Journal:  Int J Mol Sci       Date:  2022-04-10       Impact factor: 6.208

10.  Parenchymal lung abnormalities following hospitalisation for COVID-19 and viral pneumonitis: a systematic review and meta-analysis.

Authors:  Laura Fabbri; Samuel Moss; Fasihul A Khan; Wenjie Chi; Jun Xia; Karen Robinson; Alan Robert Smyth; Gisli Jenkins; Iain Stewart
Journal:  Thorax       Date:  2022-03-25       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.